Category Archives: Cell Biology

Architecture of cellcell junctions in situ reveals a mechanism for bacterial biofilm inhibition – pnas.org

Significance

Pseudomonas aeruginosa bacteria form antibiotic-tolerant biofilms that pose significant challenges in clinical settings. Overcoming these challenges requires fundamental insights into how biofilms are formed, combined with innovative strategies to disrupt biofilms. Electron cryotomography in situ data presented here reveal the arrangement of the key P. aeruginosa adhesin CdrA at biofilm cellcell junctions. Guided by our imaging data, we raised and characterized a CdrA-specific nanobody binder capable of disrupting these cellcell junctions, thereby increasing the efficacy of antibiotic-mediated bacterial killing in biofilms. Together these data provide a pathway for developing effective alternative bacterial infection treatment strategies.

Many bacteria, including the major human pathogen Pseudomonas aeruginosa, are naturally found in multicellular, antibiotic-tolerant biofilm communities, in which cells are embedded in an extracellular matrix of polymeric molecules. Cellcell interactions within P. aeruginosa biofilms are mediated by CdrA, a large, membrane-associated adhesin present in the extracellular matrix of biofilms, regulated by the cytoplasmic concentration of cyclic diguanylate. Here, using electron cryotomography of focused ion beammilled specimens, we report the architecture of CdrA molecules in the extracellular matrix of P. aeruginosa biofilms at intact cellcell junctions. Combining our in situ observations at cellcell junctions with biochemistry, native mass spectrometry, and cellular imaging, we demonstrate that CdrA forms an extended structure that projects from the outer membrane to tether cells together via polysaccharide binding partners. We go on to show the functional importance of CdrA using custom single-domain antibody (nanobody) binders. Nanobodies targeting the tip of functional cell-surface CdrA molecules could be used to inhibit bacterial biofilm formation or disrupt preexisting biofilms in conjunction with bactericidal antibiotics. These results reveal a functional mechanism for cellcell interactions within bacterial biofilms and highlight the promise of using inhibitors targeting biofilm cellcell junctions to prevent or treat problematic, chronic bacterial infections.

Prokaryotic cells including bacteria and archaea are frequently found in nature as part of surface-attached, multicellular communities called biofilms (13). Biofilms constitute the majority of bacterial biomass on Earth (1), representing a fundamental mode of bacterial existence. While bacterial biofilms may prove beneficial to eukaryotes as host-associated microbiomes (4, 5), the formation of pathogenic bacterial biofilms is associated with the establishment of serious chronic antibiotic-tolerant infections (6).

Recently, important advances have been made in understanding early events in biofilm formation (7); however, the molecular mechanisms underlying how mature biofilms are formed and stabilized are still poorly understood. One of the hallmarks of mature biofilms is the presence of an extracellular polymeric substance (EPS) matrix that binds bacterial cells together into a sessile community, promoting antibiotic tolerance and providing protection from other predatory organisms (811). The EPS matrix of biofilms is a complex mixture of molecules, consisting of proteins, polysaccharides, and extracellular DNA (12). Comprehending the spatial arrangement of molecules in the EPS matrix of biofilms has been problematic (13) due to the inherent difficulty associated with high-resolution microscopic imaging inside the tissue-like environment of a biofilm. As a result, mechanisms of cellular tethering and the architecture of cellcell junctions within biofilms are incompletely understood at the fundamental molecular level.

Nevertheless, elegant optical microscopy studies on Vibrio cholerae biofilms have provided clues to the internal organization of the EPS matrix, revealing that the proteins required for mature biofilm formation (RbmA, Bap1, and RbmC) fail to accumulate at the cell surface in the absence of an exopolysaccharide (called VPS) and that loss of RbmA function dramatically alters biofilm architecture (14, 15). In vitro studies of V. cholerae proteins have revealed an exopolysaccharide-dependent (RbmA) adhesin oligomerization pathway (16), and other studies suggest that direct interactions between the RbmA adhesin and glycans on partner cells lead to cellcell adhesion (17). In Escherichia coli, an auto-aggregating adhesin known as Antigen 43 (Ag43) has been proposed to mediate cellcell interactions in biofilms by a Velcro-like mechanism in which two Ag43 molecules from apposing cells dimerize to bind cells to each other (18). In both of these comparatively well-characterized bacterial species, direct visualization of the EPS matrix has thus far not been performed at the macromolecular scale, and the spatial arrangement of molecules at cellcell junctions remains unclear.

Pseudomonas aeruginosa is a human pathogen of critical concern, posing a significant challenge in hospital settings due to its ability to form antibiotic-tolerant biofilms (1921). Cellcell interactions in the EPS matrix of P. aeruginosa biofilms are facilitated by the expression of a 220 kDa adhesin (Fig. 1A) known as CdrA in a cyclic diguanylate (c-di-GMP)dependent manner (22). Under high cytoplasmic c-di-GMP concentrations, CdrA expression is increased, and the mature CdrA protein is tethered to the outer membrane of P. aeruginosa cells through its membrane protein partner CdrB (22, 23). In these conditions, CdrA promotes cellular aggregation and biofilm formation by directly binding to polysaccharides in the EPS matrix of biofilms, such as the Psl or Pel polysaccharides (22, 24). When cytoplasmic c-di-GMP concentrations are lower, CdrA is cleaved and released into the extracellular milieu by the action of a periplasmic protease, promoting biofilm disaggregation (22).

CdrAB expression results in the appearance of 70-nm-long, matchstick-shaped protrusions on the surface of P. aeruginosa cells. (A) Schematic representation of the CdrA sequence highlighting previously determined and predicted functional regions including a TPS (two-partner secretion) domain, putative N-terminal cleavage site, and the known carboxyl-terminal cleavage site. (B) PAO1 (Left) and PAO1 psl (Right) induced to express CdrAB and stained with fluorescent (Alexa 488) lectin to label mannose-containing polysaccharides. (C) Floccules formed by CdrAB expression before (Left) and after agitation in the presence of mannose (Right). (D) A slice through an electron cryotomogram of a P. aeruginosa PAO1 cell expressing CdrAB. (E) Three-dimensional segmentation of the boxed area in D (red dashed line). The outer membrane of the cell (purple) and matchstick-shaped cell surface molecules (green) are shown. (F) Cropped and magnified view of the boxed region from the tomographic slice shown in D (solid yellow line) with matchstick-shaped protrusions indicated (red arrowheads). (G) Length quantification of cell-surface matchstick-shaped protrusions; lengths are measured in electron cryotomograms (71 2 nm [SD, n = 108] from 12 tomograms). Refer also to SI Appendix, Fig. S1 and Movie S1.

In this study, we have performed electron cryotomography (cryo-ET) of focused ion beam (FIB)milled tissue-like multicellular specimens to image intact cellcell junctions of P. aeruginosa bacteria, revealing the arrangement of CdrA in the extracellular matrix of P. aeruginosa biofilms. We have supplemented our in situ imaging with electron cryomicroscopy (cryo-EM) and native mass spectrometry (MS) experiments on biochemically purified CdrA protein, which together show that CdrA forms an extended structure at the outer membrane, forming cellcell junctions via polysaccharide binding partners. Finally, single-domain antibodies (nanobodies) raised against purified CdrA protein provided a valuable probe to test and verify all our hypotheses experimentally on wild-type bacterial biofilms and were found to limit wild-type biofilm formation and potentiate the activity of antibiotics against mature biofilms. These data identify CdrA as a promising candidate for the development of therapeutics.

To study the molecular mechanism by which CdrA tethers cells to the EPS matrix within biofilms of P. aeruginosa, we employed an inducible expression system in which both CdrA and CdrB are expressed. A mutation in the carboxyl-terminal part of CdrA (in the sequence TAAG, described in ref. 23) prevents the cleavage and release of CdrA into the extracellular environment, locking the protein in a biofilm-promoting state. Upon expression of the biofilm-promoting CdrA adhesin and its membrane anchor CdrB, P. aeruginosa cells formed biofilm-like floccules in solution (SI Appendix, Fig. S1A). Floccules formed by a psl strain that lacked the Psl polysaccharide were smaller than in the corresponding wild-type PAO1 strain and could be disrupted by vigorous agitation alone. Floccules formed by wild-type PAO1 were extensively stained by a mannose-sensitive lectin, unlike the corresponding psl strain (Fig. 1B), and could only be fully disrupted by agitation when the medium was supplemented with an excess of D-mannose sugar (Fig. 1C and SI Appendix, Fig. S1B), demonstrating that cellcell clumping mediated by CdrAB is polysaccharide-dependent in wild-type PAO1 P. aeruginosa, confirming previous reports (22, 24). Cryo-ET of single cells expressing CdrAB, disassembled from cell clumps by vigorous vortexing in the presence of excess D-mannose, showed protrusions emanating from the P. aeruginosa cell surface (Fig. 1 DF and SI Appendix, Fig. S1 CE and Movie S1). These 3-nm-wide protrusions projected roughly orthogonally to the outer membrane of P. aeruginosa and had a broad tip, resulting in a matchstick-like appearance. The length of these matchstick-shaped protrusions was 71 2 nm (SD, n = 108), as measured in three-dimensional cryo-ET data (Fig. 1G).

To establish the identity of the matchstick-shaped protrusions, molecules in the outer membrane of P. aeruginosa cells from the inducible CdrAB expression strain were stripped and biochemically purified (Materials and Methods and SI Appendix, Fig. S2). The major component from the purification revealed a protein running at 150 kDa as a single band on a gel (Fig. 2 A, Inset and SI Appendix, Fig. S2A). Proteomic peptide fingerprinting analysis of the purified sample confirmed its identity as CdrA (SI Appendix, Fig. S2B). Next, cryo-EM of the MS-verified, purified CdrA specimen revealed matchstick-shaped filamentous particles on the grid (Fig. 2A and Movie S2). A visual inspection of these particles suggested that they closely resembled the matchstick-shaped protrusions observed in whole-cell cryo-ET (Fig. 1 DF). To probe this further, cryo-ET data of the purified sample was collected and quantified, showing that the matchstick-shaped protrusions were 71 1-nm (SD, n = 75) long (Fig. 2B), again indicating that they corresponded to the same cryo-EM density observed on the P. aeruginosa cell surface (Fig. 1 DG). To assess whether the carboxyl-terminal TRRG mutation alters the architecture of CdrA, we purified particles secreted by cells expressing wild-type CdrA (Fig. 2C) and found that native CdrA, in the same manner as the mutant, forms elongated matchstick-shaped particles, while no protein was detected in the uninduced control (Fig. 2C).

Cell-surface matchstick-shaped protrusions correspond to a mature form of CdrA. (A) Cryo-EM micrograph of protein purified from the surface of cells expressing CdrAB. Structures resembling matchstick-shaped protrusions are indicated (red arrowheads). (Inset) SDS-PAGE of the purified protein. (B) Length quantification of purified protein resembling matchstick-shaped protrusions, measured in electron cryotomograms (71 1 nm [SD, n = 75] from five tomograms). Refer also to SI Appendix, Fig. S2 and Movie S2. (C) Cryo-EM micrograph of protein purified from the surface of cells expressing wild-type CdrAB. Matchstick-shaped structures are indicated (red arrowheads). (Lower) SDS-PAGE of purified wild-type CdrA protein from an induced cdrA/pCdrAB strain (+) versus an uninduced cdrA/pCdrAB control ().

To determine the oligomerization state of CdrA in solution, the purified CdrA (TRRG mutant) protein was analyzed using native MS (SI Appendix, Fig. S2C), which showed that CdrA exists as monomers in solution. Thus, the matchstick-shaped densities observed in our cryo-ET data (Fig. 1 DF) correspond to a single copy of CdrA protein projecting from the outer membrane into the extracellular environment. The measured masses of CdrA (163,286 3 Da and 164,047 1 Da) determined by native MS agree with previous work showing that the protein undergoes proteolytic processing into a mature functional form (22, 23).

We next wished to understand how CdrA mediates cellcell interactions within the extracellular matrix of P. aeruginosa biofilms by direct visualization of cellcell junctions using high-resolution cryo-ET. We used the inducible CdrAB expression strain to promote flocculation of P. aeruginosa cells (SI Appendix, Fig. S1) and deposited these floccules onto cryo-EM grids. While P. aeruginosa cells at the edges of the cell clump could be observed (Fig. 3A), the multicellular, tissue-like specimen was too thick for direct cryo-EM imaging. To visualize the internal arrangement of the cellcell junctions, thin lamellae of these specimens were produced by cryo-FIB milling (SI Appendix, Fig. S3 A and B), which supported high-resolution imaging using cryo-ET.

FIB milling and cryo-ET of P. aeruginosa cellcell junctions. (A) Cryo-EM of biofilm-like floccules produced by P. aeruginosa cells expressing CdrAB. Cryo-EM views of the multicellular aggregate. Red arrowheads indicate cells observed at the edge of the cellular aggregate (yellow box). (B and C) Cryo-ET slices through FIB-milled specimens revealing cells (red asterisks) and cellcell junctions (white asterisks). For clarity, white arrowheads indicate ice contamination. Refer also to SI Appendix, Fig. S3.

In electron cryotomograms of cryo-FIBmilled lamellae, we observed P. aeruginosa bacterial cells in close proximity with each other (Fig. 3 B and C). A visual inspection of the cellcell junctions between the P. aeruginosa cells revealed matchstick-shaped protrusions corresponding to CdrA molecules (Fig. 4 A and B and SI Appendix, Fig. S3C). These CdrA molecules were projecting outward, away from the bacterial outer membrane and extending between P. aeruginosa cells into the intercellular space (Fig. 4C and Movie S3). The length of these CdrA molecules was 71 1 nm (SD, n = 20), in line with the observations of CdrA on single P. aeruginosa cells and also of CdrA molecules after purification (Figs. 1, 2, and 4 D and E and Movie S4). While CdrA has been shown to self-interact in the absence of polysaccharides (25), in our data, direct CdrA:CdrA linkages were never observed, nor was a Velcro-like side-by-side configuration of CdrA molecules from apposing cells seen. The lack of direct CdrA stacking, in conjunction with the known interactions between CdrA and polysaccharides (22, 24), and the ability of the monosaccharide mannose to disrupt CdrA-mediated cell clumps (Fig. 1C and SI Appendix, Fig. S1B) are all consistent with a scenario in which CdrA molecules extend out of the bacterial cell surface to tether cells through interactions with polysaccharide binding partners known to be abundant in the EPS matrix.

CdrA extends into the EPS matrix to mediate cellcell interactions. (A and B) Cryo-ET slice (A) and corresponding three-dimensional segmentation (B) of a cellcell junction within a P. aeruginosa PAO1 biofilm-like floccule. The multicellular specimen was processed by cryo-FIBmilling into thin lamellae suitable for high-resolution cryo-ET. Cell outer membranes (blue and purple) and CdrA (green) are highlighted in B. (C) Enlarged view of the boxed region in A. Comparison of CdrA at cellcell junctions within biofilm-like floccules to (D) CdrA on the surface of single cells and (E) biochemically purified CdrA in solution. CdrA is highlighted with red arrowheads. Refer also to SI Appendix, Fig. S3 and Movies S3 and S4.

To assess whether these CdrA-mediated cellcell junctions might be specifically targeted, we made use of single-domain llama antibodies (or nanobodies), which have recently been shown to be a powerful tool for structural and cell biology (26). A panel of nanobodies was raised against purified CdrA protein, and based on the ability of the nanobodies to interfere with flocculation of P. aeruginosa bacteria in our inducible expression system (SI Appendix, Fig. S1A, further discussed in SI Appendix, Fig. S5), one positive nanobody binder was selected for further experiments. This nanobody (termed NBCdrA) was coupled with 5-nm gold nanoparticles (NBCdrA-gold) and incubated with P. aeruginosa cells expressing CdrA localized to the cell surface. NBCdrA-gold labeling of these cells revealed a shell of gold particles specifically around cells expressing CdrAB, 70 nm from the cell surface (Fig. 5A). No specific NBCdrA-gold labeling was observed in control cells in which CdrA was absent from the outer membrane (Fig. 5B), confirming that the cell-surface 71-nm matchstick-shaped protrusions correspond to CdrA molecules.

Nanobody binding to CdrA on cells and in vitro. (A and B) Cryo-EM micrographs of (A) cells with induced CdrAB expression or (B) control cells, labeled with a NBCdrA-gold conjugate (red arrowheads). Cropped and magnified views of the boxed areas in each panel are shown. (C) Native mass spectra of CdrA alone (lower spectrum) or CdrA bound to the CdrA-specific nanobody NBCdrA (upper spectrum) shows binding in a 1:1 ratio. (D) A series of native MS experiments with increasing NBCdrA concentrations were performed, yielding a binding curve. Each data point shows the relative fractional intensity of NBCdrA binding peaks over total peak intensity (labeled as fractional abundance) versus NBCdrA concentration. SD (error bars) was calculated from the average of five observed charge states in three independent experiments. Refer also to SI Appendix, Fig. S4.

As a further verification, we performed native MS of a sample containing both purified CdrA and NBCdrA and observed the formation of a 1:1 complex (Fig. 5C). To probe nanobody-binding, we performed a series of native MS experiments with a constant CdrA concentration titrated against increasing NBCdrA concentrations. These native experiments were used to estimate a binding affinity of NBCdrA with CdrA of 0.75 0.26 M (SD) (Fig. 5D and SI Appendix, Fig. S4 A and B). These binding experiments in native MS validated our microscopic observation of NBCdrA-gold binding to CdrA on cells (Fig. 5 A and B). Furthermore, the 1:1 binding observed in MS, together with the localization of NBCdrA-gold 70 nm from the outer membrane, strongly suggest that a region at the broad N-terminal tip of cell-surface CdrA is specifically targeted by NBCdrA.

Given the mechanistic scenario suggested by our cellular (Fig. 1), in vitro (Fig. 2), and in situ imaging (Figs. 3 and 4) in which CdrA extends into and likely tethers cells to the EPS matrix, we next set out to determine whether this function of CdrA could be blocked by the targeted use of nanobodies to inhibit P. aeruginosa biofilm formation. First, we assessed whether the anti-CdrA nanobody (NBCdrA), the nanobody shown to bind to the broad tip of CdrA molecules (Fig. 5 A and B), could disrupt CdrA-mediated cellcell adhesion and flocculation of P. aeruginosa in our inducible CdrAB expression system. In line with our expectation, the addition of NBCdrA disrupted preformed cell clumps, causing the cells to return to a planktonic state, forming a cloudy culture (SI Appendix, Fig. S5A). This effect could be quantified by measuring the mass of cell clumps, which confirmed that cellular aggregation decreased with increasing NBCdrA concentration. In contrast, another CdrA nanobody found in our screen (NBCdrA-2) had no effect on CdrAB-mediated flocculation (SI Appendix, Fig. S5A), potentially due to its lower binding affinity for CdrA (SI Appendix, Fig. S5 BD). These observations suggest that a specific region at the tip of CdrA molecules 70 nm away from the cell (as indicated by NBCdrA-gold labeling) is critical for CdrA-mediated cellcell tethering, and blocking this region with NBCdrA leads to disruption of cellcell junctions.

To explore the effect of the nanobodies on wild-type P. aeruginosa bacteria, a custom microfluidics flow system was used to cultivate P. aeruginosa biofilms. Combining the flow system with continuous fluorescence microscopy imaging, we found that the formation of P. aeruginosa PA14 biofilms was significantly delayed upon the addition of NBCdrA (Fig. 6), showing that NBCdrA can also interfere with the function of native CdrA molecules on wild-type cells. These biofilm inhibitory effects were not observed with NBCdrA-2 (SI Appendix, Fig. S5E), confirming that NBCdrA-2 does not interfere with the adhesive function of CdrA in the EPS matrix and demonstrating again that targeted binding of NBCdrA to the tip of functional CdrA is sufficient to inhibit biofilm formation in wild-type P. aeruginosa bacteria.

Nanobody-mediated disruption of CdrA inhibits biofilm formation. (A) Biofilms of P. aeruginosa PA14 expressing TFP (teal fluorescent protein) were cultivated in the presence or absence of NBCdrA and monitored over 10 h under microfluidics flow cell conditions. Representative images are shown. (B) Quantification of fluorescence in the experiments described in A. Each time point represents three images per time point from at least three independent experiments (error bars show SD). Statistical significance was assessed using the Students t test at all times points (****P < 0.0001 at all times at or after 2.5 h post treatment). Refer also to SI Appendix, Fig. S5.

NBCdrA access to cell-surface CdrA is likely to be greater in immature, developing biofilms in which cellcell junctions have not yet formed and in which diffusion deep into a multicellular specimen is not needed. We next investigated whether preformed, mature P. aeruginosa biofilms could also be disrupted by NBCdrA. Using the same flow setup, we found that bacterial cells in preformed PA14 biofilms were efficiently killed when an otherwise sublethal colistin antibiotic treatment was supplemented with NBCdrA (Fig. 7 A and B and Movie S5). The efficacy of bacterial killing was substantially increased when NBCdrA was added earlier, during biofilm development, before the addition of colistin (Fig. 7 A and B), in line with our data demonstrating the inhibitory effect of NBCdrA on developing biofilms (Fig. 6). PAO1 biofilms were similarly susceptible to colistin-mediated bacterial killing when pretreated with NBCdrA, although a higher concentration of nanobody was required to achieve a similar effect (Fig. 7C and SI Appendix, Fig. S6). These results using wild-type P. aeruginosa biofilms demonstrate the key role of the CdrA protein in mediating cellcell interactions and highlight the importance of these interactions for effective biofilm formation, which directly promote tolerance of those biofilms to antibiotic treatment.

Nanobody-assisted bacterial killing in preexisting, mature biofilms. (A) Biofilms were grown in a microfluidics flow setup either in the presence (NBCdrA pretreatment) or absence (No-nanobody or NBCdrA treatment) of NBCdrA. After 10 h, NBCdrA was added to the NBCdrA treatment condition, and all samples were treated with PI (propidium iodide) and a sublethal dose of colistin (1 g/mL) and imaged for a further 10 h. Fluorescence microscopy images with TFP (blue) for live cells or PI staining (red) for dead cells are shown. (B) Quantification of fluorescence in the experiments described in A, following the addition of colistin. The ratio of PI to TFP fluorescence was calculated over three replicate experiments (error bars denote SD). Statistical significance was assessed using the Students t test for all time points (****P < 0.0001, for times after 6 to 7 h versus the no-nanobody control). (C) Quantification of fluorescence in the experiments performed on PAO1 strain of P. aeruginosa, following the addition of colistin. The ratio of PI to green fluorescent (GFP) fluorescence was calculated over three replicate experiments (error bars denote SD). Statistical significance was assessed using the Students t test for all time points (****P < 0.0001) for times after 10 h versus the no-nanobody control). Refer to SI Appendix, Fig. S6 for images.

Our results establish that functional cell-surface CdrA forms an extended structure, projecting into the EPS matrix, to mediate cellcell interactions. This arrangement is consistent with CdrA acting as a molecular tether, in which copies of CdrA anchored on the cell surface at their C termini may be glued at their N-terminal adhesive regions by secreted polysaccharides, known to be abundant in the EPS matrix of P. aeruginosa and previously shown to interact with CdrA (13, 24). Our results demonstrate that CdrA is a major adhesin mediating biofilm formation in wild-type P. aeruginosa and show that adhesins with similar roles, such as LecB (27), cannot effectively compensate for its disruption. The difference in the sensitivity of different P. aeruginosa strains (PA14 and PAO1) to NBCdrA treatment (Fig. 7) suggests variability in the contribution of CdrA or its accessibility during biofilm formation.

Nevertheless, while the exact contribution of different adhesins in P. aeruginosa biofilm development will require detailed experiments to delineate, the prominent role of CdrA-mediated cellcell junctions is highlighted by our experiments. Our reconstituted cell flocculation system used a nonLapG-cleavable mutant of CdrA, which was important for in situ imaging using cryo-ET. Future innovative assays will be needed to replicate structural studies with wild-type CdrA protein at cellcell junctions. The wild-type protein, natively secreted from cells, had the same overall architecture as the carboxyl-terminal nonLapG-cleavable mutant of CdrA (Fig. 2C). We predict that this mutation at the carboxyl-terminal membrane anchor 70 nm away from the adhesive tip of CdrA will have little or no effect on its adhesive function, as indicated by the ability of CdrA(TRRG) to form cellcell junctions in our assays.

This paradigm of a bacterial adhesin interacting with the EPS matrix is functionally distinct from either the alternative Velcro-like mechanism of cellcell adhesion proposed for E. coli Ag43 (18) or from the more nuanced case of V. cholerae in which multiple adhesins and exopolysaccharides appear to regulate cellcell interactions (14, 16). In both E. coli and V. cholerae, the spatial organization of cellcell junctions in biofilms has not yet been observed experimentally at high resolution, and further research will be needed to understand the arrangement of these junctions at the molecular level. In our in situ cryo-ET data, while CdrA proteins were observed, extracellular polysaccharides could not be resolved. It therefore remains to be described how polysaccharides are arranged in the EPS matrix in relation to bacterial cells and other matrix molecules. While it is possible that direct CdrA:CdrA interactions may additionally stabilize P. aeruginosa cell junctions in some strains (25), these were not observed in our data.

Recently, latest generation optical microscopy techniques have proven invaluable in providing novel insights into bacterial biofilm formation (14, 15, 28). In this study, we have leveraged the latest cryo-ET techniques to reveal the arrangement of cellcell junctions that are of key importance in biofilm formation. This study highlights the utility of FIB milling and cryo-ET to deliver high-resolution insights into tissue-like multicellular specimens, which have traditionally been considered beyond the reach of structural cell biology. With increasing throughput and automation of these methods (29, 30), structure determination of molecules in cellcell junctions may become practical and a possible extension of this work in the future.

Moreover, we also show that biofilm formation in wild-type P. aeruginosa bacteria can be inhibited by targeting the filamentous CdrA adhesin with a nanobody binder that interacts with the tip of the functional protein in a 1:1 ratio. Although gold-labeled nanobody was concentrated 70 nm away from the outer membrane of P. aeruginosa bacteria at the tip of CdrA adhesins, identifying the exact epitope of nanobody-binding to CdrA will require higher resolution structural data. Our results are consistent with the scenario in which nanobody-binding precludes the interaction between CdrA and polysaccharides in the EPS matrix (Fig. 8). This nanobody was further shown to promote the activity of an antibiotic in killing bacterial cells in a preformed wild-type P. aeruginosa biofilm. The strategy of neutralizing biofilm adhesion mechanisms may also be applicable to similar large cell-surface adhesins such as the filamentous hemagglutinin of Bordetella pertussis (31) and the repeat-in-toxin domain-containing adhesins such as SiiE of Salmonella enterica and LapA from Pseudomonas fluorescens (3234). Such an approach may also be useful in treating bacteria whose adhesins utilize alternative proposed cellcell adhesion mechanisms, such as Ag43 of E. coli (18) or RbmA of V. cholerae (16).

CdrA-mediated cellcell junctions. Schematic depiction of the mechanism of biofilm inhibition by targeting CdrA revealed in this study. Refer also to Movie S5.

While neutralizing therapies now represent an important treatment route for many diseases, they remain relatively underexploited in the field of antimicrobials (35, 36). In the context of the increasing challenges posed by the emergence of antimicrobial resistance (37, 38), our results highlight how specific adhesins on the surface of bacterial cells may serve as promising targets for biofilm inhibition or for the prevention of chronic infections in a medical setting.

Refer also to SI Appendix, Supplementary Text for further details.

For CdrAB(TRRG) expression, an arabinose-inducible pMQ72 plasmid system was used, as described in ref. 23, and transformed into the PAO1 pslBCD or PAO1 cdrA strains, described in ref. 22. The strains PAO1 psl pMQ72-cdrAB(TRRG) and PAO1 cdrA pMQ72-cdrAB(TRRG) were tested alongside a PAO1 cdra pMQ72 empty vector control. Cultures were induced with arabinose to induce flocculation. To disaggregate cells, floccules were briefly vortexed with (for strains with wild-type Psl) or without (for the Psl deletion strain) the addition of 0.5% mannose (weight/volume). To stain for Psl-containing sugars, floccules were pelleted and resuspended in 80 g/mL Alexa488-conjugated Narcissus pseudonarcissus lectin (Glycomatrix) for 30 min at 4 C, washed three times with phosphate-buffered saline (PBS), and deposited on a glass slide ahead of imaging. Microscopy of floccules was performed using a Zeiss Axio Imager M2 microscope.

To purify CdrA, subcultures of PAO1 pslBCD pMQ72-cdrAB(TRRG) were plated on lysogeny broth agarsupplemented with gentamicin and arabinose to induce CdrAB expression and incubated overnight at 37 C. The following day, cells were scraped from the plates into PBS, vortexed to shear CdrA from the outer membrane, and centrifuged to remove cells. The supernatant was precipitated with polyethyleneglycol 6,000 and centrifuged to remove contaminating proteins. The resulting soluble CdrA sample was dialyzed and purified by anion exchange chromatography. Eluted fractions were analyzed by sodium dodecyl sulfatepolyacrylamide gel eletrophoresis (SDS-PAGE), and fractions containing CdrA were further purified by size exclusion chromatography.

Antibodies to CdrA were raised in a llama by intramuscular immunization with purified protein using Gerbu LQ#3000 as the adjuvant. Total RNA was extracted from blood, and VHH complementary DNAs were generated by RT-PCR. The pool of VHH-encoding sequences was amplified by two rounds of nested PCR and cloned into the SfiI sites of the phagemid vector pADL-23c. Electro-competent E. coli TG1 cells were transformed with the recombinant pAD-23c vector, and the resulting TG1 library stock was infected with M13K07 helper phage to obtain a library of VHH-presenting phages. Phages displaying VHHs specific for CdrA were enriched via two rounds of bio-panning on biotinylated CdrA, and individual phagemid clones were picked. VHH-displaying phages were recovered by infection with M13K07 helper phage and tested for binding to CdrA by enzyme-linked immunosorbent assay (ELISA). Phage binders were ranked according to the ELISA signal and grouped according to CDR3 sequence identity.

To express nanobodies, nanobody phagemids were first transformed by heat shock into WK6 E. coli cells. Subcultures of transformants were prepared and induced with isopropyl -D-thiogalactoside and incubated overnight. The following day, cells were pelleted, resuspended in a lysing buffer, and homogenized. His-tagged nanobodies were purified by Ni-NTA affinity chromatography and size exclusion chromatography.

Data were collected on a Q-Exactive ultrahigh mass range mass spectrometer (Thermo Fisher Scientific) and analyzed using Xcalibur 4.2 (Thermo Fisher Scientific) and UniDec (39) software packages. Nanobody-binding experiments were performed by adding increasing amounts of NBCdrA to a constant 2 M CdrA. The resulting calculated binding affinity (KD) from native MS was determined by employing a nonlinear regression curve fitting for one-site specific binding in GraphPad Prism 8.0.

For protein identification, tryptic peptides were obtained by digesting the protein sample with trypsin as described in ref. 40. Peptides separated using a chromatographic system connected to an Eclipse Tribrid Orbitrap mass spectrometer (Thermo Fisher Scientific). Raw data files were processed for protein identification using MaxQuant (version 1.6.3.4) and searched against the UniProt database.

NBCdrA was dialyzed into 20 mM Tris pH 7.4, 150 mM NaCl, and incubated with a 2.5 molar excess of Ni-NTA 5-nm gold (Nanoprobes) for 30 min at room temperature. Unbound gold was separated from NBCdrA-gold using a PD-10 desalting column. To label cells, NBCdrA-gold was incubated with PAO1 cdrA pMQ72-cdrAB(TRRG) floccules followed by the addition of mannose ahead of cryo-EM sample preparation.

To assess the efficacy of nanobody-mediated floccule disaggregation, PAO1 cdrA pMQ72-cdrAB(TRRG) bacterial floccules were incubated with NBCdrA or NBCdrA-2. Floccules were pelleted at 300 g for 5 min. The supernatant was removed, and the remaining cells were pelleted at 15,000 g for 15 min. The two pelleted fractions were weighed, and floccule mass was calculated as a percentage of total cell mass.

To determine the effect of nanobodies on the formation of wild-type biofilms, a previously described flow system was used (41). P. aeruginosa PA14 or PAO1 was visualized via fluorescence of the teal fluorescent protein (TFP) or green fluorescent protein (GFP), respectively. Biofilms were grown and visualized in microfluidics chambers generated through soft lithography techniques (42, 43). Bacteria were prepared as described previously (44). Bacterial cultures were allowed to attach for 1 h without flow, after which the flow rate was set to 1.0 L/min and imaged for 10 to 12 h, as indicated.

For the biofilm inhibition assays, the biofilm medium was supplemented either with no-nanobody, 0.3 mg/mL NBCdrA (PA14 cells), or 0.8 mg/mL NBCdrA (PAO1 cells) as indicated and imaged for 10 h postinoculation. To test the impact of colistin on a preformed biofilm, bacteria were prepared, inoculated, and grown in microfluidics chambers as described above. After 10 h of allowing the biofilm to establish in the absence of any treatment, KA medium was switched with KA medium supplemented with propidium iodide (PI) and 1.0 g/mL colistin +/ NBCdrA, as indicated and imaged for an additional 10 h of incubation.

Cryo-EM samples were prepared by depositing 2.5 L of bacterial floccules, disaggregated bacterial floccules (single cells), or NBCdrA-goldlabeled cells onto freshly glow discharged Quantifoil grids. Samples were fixed with 1% paraformaldehyde applied directly on the grid and manually blotted. Next, buffered fiducial gold was added, and the grid was blotted and plunge-frozen into liquid ethane using a Vitrobot Mark IV (Thermo Fisher Scientific).

Cryo-FIB milling of plunge-frozen biofilm-like floccules was performed as described previously (45) on a Scios DualBeam FIB/scanning electron microscope (SEM) microscope (FEI/Thermo Fisher Scientific) equipped with a Quorum PP3010T cryo-FIB/SEM preparation system. The loading stage and milling procedure were adapted, with minor alterations, from ref. 46. Grids were sputter-coated with platinum before milling and coated with a layer of organometallic platinum. Ion beam current for milling was reduced stepwise while adjusting the stage tilt as described in ref. 45. Final polishing of the lamellae resulted in 150- to 300-nm-thick lamellae.

Tilt series data were collected on a Titan Krios microscope (Thermo Fisher Scientific) operating at 300 kV fitted with a Quantum energy filter (Gatan) and direct electron detector (Gatan) using SerialEM software (47). A dose-symmetric tilt scheme was employed for cryo-ET data (48). Untilted video frame stacks of purified protein were collected on the same microscope using EPU software (Themo Fisher Scientific). Cryo-EM images of NBCdrA-goldlabeled cells were collected on a Talos Arctica 200 kV cryo-ET (Thermo Fisher Scientific).

Tilt series alignment was carried out using the eTOMO graphical user interface in the IMOD software (47). CTF (contrast transfer function) parameters for the aligned stacks were estimated using CTFFIND (49), and data were reconstructed using Tomo3D (50). Contrast in cryo-ET data were enhanced via the tom_deconv deconvolution as described in ref. 51 or via bandpass and Laplacian filtering as implemented in Fiji (52). Segmentation of image data were performed manually in IMOD (47).

All study data are included in the article and/or supporting information.

T.A.M.B. is a recipient of a Sir Henry Dale Fellowship, jointly funded by the Wellcome Trust and the Royal Society (202231/Z/16/Z). T.A.M.B. thanks the Vallee Research Foundation and the John Fell Fund for support. G.A.O. acknowledges support from the NIH (R37-AI83256), and C.V.R. acknowledges funding from the Medical Research Council (MR/N020413/1). J.H. is funded by the Edward Penley Abraham Cephalosporin Fund, and Protein Production United Kingdom is supported by the Rosalind Franklin Institute Engineering and Physical Sciences Research Council Grant EP/S025243/1. We thank Adam Costin for help with cryo-EM imaging, Carey Nadell for providing the microfluidics chambers, and Wanda Kukulski for facilitating FIB milling experiments. We would like to acknowledge the MRC Laboratory of Molecular Biology Electron Microscopy Facility for access to cryo-FIB sample preparation.

Author contributions: C.E.M. and T.A.M.B. designed research; C.E.M., J.R.B., S.K.-L., D.B.M., P.C.H., J.H., M.R.W., L.M.E., J.B., A.N.M., C.J.H., and T.A.M.B. performed research; J.R.B., S.K.-L., P.C.H., J.H., M.R.W., L.M.E., J.B., R.J.O., C.V.R., and G.O. contributed new reagents/analytic tools; C.E.M., J.R.B., S.K.-L., D.B.M., L.M.E., J.B., R.J.O., C.V.R., G.A.O., and T.A.M.B. analyzed data; and C.E.M. and T.A.M.B. wrote the paper.

The authors declare no competing interest.

This article is a PNAS Direct Submission.

This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2109940118/-/DCSupplemental.

Go here to see the original:
Architecture of cellcell junctions in situ reveals a mechanism for bacterial biofilm inhibition - pnas.org

A single dose of Covishield vaccine induced high neutralizing antibody and T cell responses – Sri Lankan study – nation.lk – The Nation Newspaper

A study in Sri Lanka has found that 93.4% individuals developed antibodies to a single dose of the Covishield vaccine, the made-in-India variant of Oxford-AstraZenecas AZD-1222 formulation, while 97.1% developed neutralizing antibodies.

With the initiation of the COVID-19 vaccination program, Health Care Workers in Sri Lanka were the first to be vaccinated with Covishield vaccine.

Therefore, the Allergy, Immunology and Cell Biology Unit, Department of Immunology Molecular and Molecular Medicine investigated antibody responses to the SARS-CoV-2, neutralizing antibody responses, antibody responses to the variants, along with T cell responses.

The full article is available here at Nature Communications, which has an impact factor of 14.9:Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers | Nature Communications

93.4% individuals developed antibodies to a single dose of the vaccine and 97.1% developed neutralizing antibodies. There was no difference in immune responses in younger individuals compared to those >60 years of age.

The vaccine induced potent T cell responses with 67.1% developing T cell responses. However, the antibody responses to the beta SARS-CoV-2 virus variant was low. Antibodies to delta was not measured, as delta was not a problem during the time the study was conducted (February and March 2021).

The research team included scientists from the Allergy, Immunology and Cell Biology Unit, Department of Immunology Molecular and Molecular Medicine, Colombo Municipality Council and University of Oxford.

The funding for this study was provided by the World Health Organization, UK Medical Research Council and the Foreign and Commonwealth Office and the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China.

The group is also studying immune responses to other vaccines such as Sputnik, Moderna and Sinopharm and how the immunity to these different vaccine persist and compare with natural infection.

The most recent preprint on the immune responses to the Covishield vaccine at 16 weeks is available here:Immune responses to a single dose of the AZD1222/Covishield vaccine at 16 weeks in individuals in Sri Lanka | medRxiv

Source: USJ

View post:
A single dose of Covishield vaccine induced high neutralizing antibody and T cell responses - Sri Lankan study - nation.lk - The Nation Newspaper

New Research Helps Explain the Diversity of Life and Paradox of Sex – SciTechDaily

New University of Arizona research finds that sexual reproduction and multicellularity drive diversity among different species.

There are huge differences in species numbers among the major branches of the tree of life. Some groups of organisms have many species, while others have few. For example, animals, plants, and fungi each have over 100,000 known species, but most others such as many algal and bacterial groups have 10,000 or less.

A new University of Arizona-ledstudy, published in the Proceedings of the Royal Society B, tested whether sexual reproduction and multicellularity might help explain this mysterious pattern.

We wanted to understand the diversity of life, said paper co-authorJohn Wiens, a professor in theDepartment of Ecology and Evolutionary Biology. Why are most living things animals, plants, and fungi?

To address this, Wiens worked with a visiting scientist in his lab, Lian Chen from Nanjing Forestry University in China. They estimated rates of species proliferation in 17 major groups that spanned all living organisms, including bacteria, protists, fungi, plants and animals. The hard part was to estimate how many species in each group were multicellular versus unicellular and how many reproduced sexually versus asexually. For five years, Chen sifted through more than 1,100 scientific papers and characterized the reproductive modes and cellularity of more than 1.5 million species.

They found that both multicellularity and sexual reproduction helped explain the rapid proliferation of animal, plant and fungal species. The rapid proliferation of these three groups explains why they now include more than 90% of Earths known species.

The duo also found that the rapid proliferation of sexual species may help explain the paradox of sex. The paradox is why so many species reproduce sexually, despite the disadvantages of sexual reproduction.

For sexual species, only half the individuals are directly producing offspring. In an asexual species, every individual is directly producing offspring, Wiens said. Sexual reproduction is not as efficient. Another disadvantage of sexual reproduction is that you do need two individuals to make something happen, and those two individuals have to be the right sexes. Asexual species, on the other hand, only need one individual to reproduce.

Chen and Wiens found a straightforward answer to the paradox of sex. The reason why there are so many sexual species is because sexual species actually proliferate more rapidly than asexual species. This had not been shown across all of life before.

They also found that another explanation for the large number of sexual species is that sexual reproduction and multicellularity are strongly associated across the tree of life, and that multicellularity helps drive the large number of sexual species.

Multicellularity is actually more important than sexual production. We did a statistical analysis that showed it is probably at least twice as important for explaining these patterns of diversity as sexual reproduction, Wiens said.

And while this study alone cant pinpoint exactly why multicellularity is so important, researchers have previously suggested that it has to do with the variety of cell types within a multicellular organism.

If youre a single cell, theres not much variety there, Wiens said. But multicellularity allows for different tissues or cell types and allows for diversity. But how exactly it leads to more rapid proliferation will need more study.

Chen and Wiens also tested how their conclusions might change if most living species on Earth were species of bacteria that are still unknown to science.

Most bacteria are unicellular and asexual. But because bacteria are much older than plants, animals, and fungi, they have not proliferated as rapidly, even if there are billions of bacterial species, Wiens said. Therefore, multicellularity and sexual reproduction still explain the rapid proliferation of animals, plants, and fungi.

Future work will be needed to understand how multicellularity and sexual reproduction drive biodiversity. Wiens is also interested in how some groups are both multicellular and reproduce sexually yet dont proliferate rapidly.

We have some ideas, he said. One example is rhodophytes, the red algae. These are mostly marine, and we know from animals that marine groups dont seem to proliferate as rapidly.

Reference: Multicellularity and sex helped shape the Tree of Life by Lian Chen and John J. Wiens, 28 July 2021, Proceedings of the Royal Society B.DOI: 10.1098/rspb.2021.1265

Read more:
New Research Helps Explain the Diversity of Life and Paradox of Sex - SciTechDaily

Lunaphore Technologies, University of Bern Partner on Colorectal Cancer Study – GenomeWeb

NEW YORK Lunaphore Technologies said on Thursday that it has partnered with the University of Bern to study tumor budding in colorectal cancer.

The partners will use Lunaphore's Comet immunostaining platform to study colorectal cancer tumor buds, which the company said are defined as a single tumor cell or a cluster of up to four cells that are lying at the invasive front of the primary tumor site and can be seen streaming through the stroma and entering vessels.

The platform, which combines a high-throughput stainer and a fluorescent microscope, will enable multiplexed immunostaining of tumor buds and the surrounding microenvironment in cancer tissue sections, according to Tolochenaz, Switzerland-based Lunaphore.

"We believe that [tumor buds] are a key component in the process of tumor dissemination and metastasis," Inti Zlobec, director of the translational research unit at the University of Bern's Institute of Pathology, said in a statement. "This project will be crucial to further our understanding of their biology and to extract novel prognostic factors from the tumor microenvironment."

The collaboration is being funded with a grant from the Swiss Innovation Agency.

In early 2020, Lunaphore raisedabout $2.1 million in Series C2 financing.

Read the rest here:
Lunaphore Technologies, University of Bern Partner on Colorectal Cancer Study - GenomeWeb

Autophagy disruption may be at the root of early cognitive changes in Huntingtons disease – News-Medical.Net

Huntington's Disease (HD) is a progressive neurodegenerative condition characterized by motor, cognitive, and psychiatric symptoms, and motor symptoms are often preceded by cognitive changes. Recent evidence indicates that autophagy plays a central role in synaptic maintenance, and the disruption in autophagy may be at the root of these early cognitive changes. Understanding this mechanism better may help researchers develop treatments for patients with HD early in their disease progression, report scientists in a review article published in the Journal of Huntington's Disease.

In this review, experts describe how autophagy, the cellular process responsible for clearing old or damaged parts of the cell, plays a critical role supporting synaptic maintenance in the healthy brain, and how autophagy dysfunction in HD may thereby lead to impaired synaptic maintenance and thus early manifestations of disease. The line of research discussed in this review represents a previously unexplored avenue for identifying potential disease-modifying therapies for HD.

Like many neurodegenerative conditions affecting primarily cognition, such as Alzheimer's disease, preclinical and clinical data indicate that synapses, the part of brain cells responsible for communication between cells, are affected early in HD. We have long thought that autophagy played a role in the pathophysiology of HD, but what this role is has been unclear until recently. Recent evidence indicates that autophagy may be important in maintaining the synapse. This line of research has the potential to lead to identification of a drug target to treat HD early in the disease process."

Hilary Grosso Jasutkar, MD, PhD, Department of Neurology, Columbia University, and Ai Yamamoto, PhD, Departments of Neurology and Pathology and Cell Biology, Columbia University, New York, NY, USA

The authors first explore how cognitive dysfunction is an early manifestation of HD, and that similarly to other neurodegenerative diseases that primarily affect cognition, such as Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia, early deficits in synaptic function may underlie these cognitive symptoms. Next, they review the growing evidence that the lysosome-mediated degradation pathway autophagy plays a central role in synaptic maintenance, and how the disruption in autophagy may contribute to early cognitive changes in HD.

The authors conclude that there are pathologic and imaging data in individuals with mutations in the Huntingtin protein (mHtt), as well as evidence from animal models with HD, that suggest that synapse dysfunction may occur early in HD, prior to cell death.

"Autophagy plays a specialized role in the maintenance and function of the synapse, and mHtt may disrupt this function, leading to the early synaptic changes seen in HD patients and model systems," explained Dr. Grosso Jasutkar. "These synaptic changes may then manifest as impairments in synaptic plasticity and thus cognitive changes early in the disease course. Given that neurons rely on synaptic input and feedback for cell health, it is possible that this disruption in synaptic signaling in and of itself contributes to cell death in HD."

"There is much work yet to be done in this field," added Dr. Yamamoto. "Although various groups have demonstrated individual components of this pathway, a direct causal relationship of mutant Htt leading to synaptic dysfunction and, in turn, cognitive impairments, has yet to be demonstrated."

"If the model described here is borne out, therapeutics aimed at enhancing the efficiency of synaptic autophagy early in the course of HD could be protective against early cognitive changes and potentially degeneration itself," concluded the authors.

HD is a fatal genetic neurodegenerative disease that causes the progressive breakdown of nerve cells in the brain. An estimated 250,000 people in the United States are either diagnosed with, or at risk for, the disease. Symptoms include personality changes, mood swings and depression, forgetfulness and impaired judgment, unsteady gait, and involuntary movements (chorea). Every child of an HD parent has a 50% chance of inheriting the gene. Patients typically survive 10-20 years after diagnosis.

Source:

Journal reference:

Grosso Jasutkar, H & Yamamoto, A., (2021) Do Changes in Synaptic Autophagy Underlie the Cognitive Impairments in Huntingtons Disease?. Journal of Huntington's Disease. doi.org/10.3233/JHD-200466.

Read this article:
Autophagy disruption may be at the root of early cognitive changes in Huntingtons disease - News-Medical.Net

Synthetic Biology Could Be the Next Big Thing. Here Are 3 Stocks. – Barron’s

Synthetic biology is in its infancy, but its drawing comparisons to the internet of a generation ago. Bill Gates, Cathie Wood, and venture capitalist John Doerr are among those who are investing in synthetic biology companies.

What excites investors is the promise of programming the DNA of microorganisms like yeast as if they were computers and getting them to produce products more cheaply and with a lower carbon footprint than traditional manufacturing.

Synthetic biology could reduce the need for petroleum-based chemicals as well as for plant- and animal-based products, benefiting the environment. Proponents say that the total addressable market is over $1 trillion.

This is what it might have been like 25 years ago if some guy had walked up to you and said the internet was going to be an amazing investment and you had no idea what he was talking about, says Rick Schottenfeld, the general partner of the Schottenfeld Opportunities fund, an investor in Amyris. This is where we are with synthetic biology.

Yet for all the bold claims and hopes for an industry once known as industrial biotech, revenue overall currently totals less than $1 billion. And no one is making a profit.

Synthetic biology has so far produced mostly niche products like squalane, a moisturizer formerly sourced from shark liver; vitamin E; a sugar substitute; and vanillin. Amyris, which makes an estimated 70% of the worlds squalane using engineered yeast cells and sugar cane, says its efforts have saved as many as three million sharks a year.

The small scale of the industry at present hasnt dimmed investor interest in the three main plays on synthetic biology: Amyris (ticker: AMRS), Zymergen (ZY), and Ginkgo Bioworks. Ginkgo is due to go public in the current quarter through a merger with Soaring Eagle Acquisition (SRNG), a special-purpose acquisition company, or SPAC. It will be renamed Ginkgo Bioworks Holdings.

Investors may want to take a basket approach to the stocks. The combined market value of the three is $25 billion.

Synthetic biology, which blends biotechnology and industrial chemistry, isnt an easy concept to grasp. The magic of biology, Ginkgo CEO Jason Kelly has noted, is that cells run on something akin to a computers digital code. Instead of zeros and ones, the four DNA base pairs adenine, cytosine, guanine, and thymine guide cells.

Think of synthetic biology as hijacking the natural biology of the cell and reprogramming it to produce something of interest, says Doug Schenkel, a Cowen analyst who has Outperform ratings on Amyris and Zymergen. Rather than have yeast make beer, you hijack it to make the scent of a flower.

Programming DNA, of course, is harder than programming computers, but progress is coming quickly.

With impressive DNA coding capabilities, Ginkgo views itself as the industrys Amazon Web Services, working with companies in consumer, pharmaceutical, and agricultural areas to design microorganisms and cells from mammals to make desired products or drugs. It provided help to Moderna (MRNA) in its development of the Covid-19 vaccine.

Ginkgo is looking to build a platform to make biology and cells as easy to program as computers, says Kirsty Gibson, a portfolio manager at Baillie Gifford, which is buying stock in Ginkgo as part of the SPAC deal. Whats really exciting is that its not limited by industry verticalsagricultural, flavor and fragrances, pharmaceuticals, food.

Amyris controlling shareholder is one of the countrys most successful venture capitalists, John Doerr, who was an early investor in Alphabet (GOOGL) and Amazon.com (AMZN).

I believe synthetic biology will continue to be a big part of making our planet healthier and our future more sustainable, Doerr tells Barrons. Amyris is delivering on the promise of synthetic biology. Doerr is chairman of Kleiner Perkins, the Silicon Valley venture-capital firm.

Synthetic-biology manufacturing often involves large fermentation tanks filled with genetically re-engineered microorganisms like yeast that are filtered out of the finished product. This manufacturing technique uses little energy, but is unproven on a major scale.

Amyris is the furthest along, based on revenue and products. It projects $400 million in 2021 sales and break-even results based on earnings before interest, taxes, depreciation, and amortization, or Ebitda. Amyris, whose shares trade around $13.50, is valued at $4 billion and looks like the best bet. Its CEO, John Melo, sees a potential $2 billion in sales and $600 million of Ebitda in 2025.

With an all-star investor lineup including Gates Cascade Investment, Ginkgo has generated the most buzz. Based on the SPAC transaction, it has the highest market value of the threeabout $18 billion. Its projected 2021 revenue, however, is very modest, about $100 million.

Perhaps reflecting its lofty valuation, Soaring Eagle Acquisition shares havent budged since the May SPAC deal. The result is that investors can buy the stock for $9.95, a slight discount to the price of $10 at which several prominent investment firms including Cathie Woods Ark Investment Management and Baillie Gifford, an early backer of Tesla (TSLA), agreed to invest $775 million as part of the SPAC merger with Ginkgo.

Ginkgo calls its microorganism design fees foundry revenues. It has royalty deals or equity stakes in 54 partners, and is working with Bayer (BAYRY), Roche Holding (RHHBY), Sumitomo Chemical (4005.Japan), and Robertet (RBT.France), a maker of flavors and fragrances.

Zymergen, which went public in April at $31, is focused on consumer electronics. It has developed a durable optical film called Hyaline, which can be used on foldable cellphones and tablets. Now trading around $35, Zymergen is valued at $3.5 billion. SoftBank Goups (SFTBY) venture fund and Baillie Gifford are investors.

E=estimate. *SRNG is in the process of merging with Ginkgo Bioworks, with the result of Ginkgo becoming a publicly-traded company. **Since IPO earlier this year. Note: Ginkgo sales are foundry only; SRNG market value is post Ginkgo merger.

Sources: Bloomberg; company reports; HSBC

Amyris shares have doubled this year as the company has delivered strong revenue growth.

Amyris takes sugar, selling for under 50 cents per kilogram (22 cents a pound), and converts it into skin creams and other direct consumer-care products that retail for over $50 for a 50 milliliter bottle (1.7 ounces), wrote HSBC analyst Sriharsha Pappu in initiating coverage of Amyris with a Buy rating and $20 price target.

The company uses bioengineered yeast to produce an array of products from sugar cane, including vitamin E, squalane, vanillin (the flavoring for vanilla), and a sugar substitute using a compound called Reb M that is normally found in the stevia plant.

The vanillin, CEO Melo says, is equivalent in quality to Madagascar vanillin and is sustainably produced from sugar cane. We dont have to worry about water or land use or child labor. Madagascar is the worlds top producer of vanillin.

Cosmetics are a major focus. Amyris launched the Biossance line of products in 2017, selling directly to consumers and through retailers like Sephora. A major ingredient in many Biossance products is squalane, a version of squalene, a naturally occurring moisturizer in the skin.

Melo sees the companys consumer branded business, including Biossance and Purecane, a sugar substitute, as the key growth drivers. Up next is an acne product. Amyris is also an ingredient supplier. Melo sees branded products generating $150 million of sales this year, up from about $50 million in 2020, and topping $300 million in 2022.

Amyris has introduced its own brands and built its own factories, in contrast with Ginkgo, which pursues an asset-light strategy of developing microorganisms and letting partners do the manufacturing and marketing.

Our focus and what makes us successful is that weve figured out which products to go into first to drive real revenue and a business rather than being a science experiment, says Melo, who isnt fond of the Ginkgo approach, saying that it has yielded little in the way of recurring revenue so far. Having your own factory is critical. It [manufacturing] is the bottleneck today for unleashing the power of synthetic biology.

Newsletter Sign-up

Get a sneak preview of the top stories from the weekend's Barron's magazine. Friday evenings ET.

It also matters for profits. When we sell a kilo of squalane directly to the consumer, we get $2,500 per kilo, Melo says. When I sell it to another beauty company, I am getting about $30 per kilo. $30 versus $2,500think about that math.

Randy Baron, a portfolio manager at Pinnacle Associates, believes that there is huge potential in Amyris. It could generate 35% top-line growth for the next decade-plus, he says. Trading at a big discount to Ginkgo, Amyris could hit $30 by the end of this year and $75 by the end of 2022, he says.

Zymergens goal is to develop bioengineered products in half the time and at a tenth the cost of conventional manufacturing. None of its products are on the market yetits Hyaline film is now being evaluated by partners. Zymergen is also developing an insect repellent free of DEET, a chemical that makes many consumers uneasy.

Zymergen has a large addressable market, and it can work with different host microbes, says Cowen analyst Schenkel, referring to yeast, bacteria, and fungi. He has an Outperform rating on the stock. If it can succeed with Hyaline, there will be greater confidence that it can succeed with some of the 10 other disclosed products in development.

Ginkgo generates revenue from allowing companies to use its cell-programming infrastructure. In a presentation, Ginkgo projected that cell programming, or foundry revenue, would rise to $1.1 billion in 2025 from $100 million this year.

CEO Kelly says this revenue understates the value creation because of the royalties or the equity stakes in its customers, which the company put at roughly $500 million. Ginkgo projected that it could have over 500 partner programs by 2025, up almost tenfold from now. Kelly says it will take time for royalties to materialize, but the rising value of the stakes is an indication of value creation.

We are effectively an app store or ecosystem for folks to write cell programs and bring them to market, he says. We improve with scale. The more programs we develop, the better it gets. Its a network effect.

The CEO plays down the manufacturing issue, noting that it isnt a problem in drug development, where the company has a focus. Amyris business is bringing products to market; Ginkgo is the app store, he says.

Its too early to say whether synthetic biology will live up to the hype, but these three stocks looked poised to manufacture gains for investors.

If a small percentage of programs that Ginkgo and Zymergen are working on become real, says Cowens Schenkel, the revenue numbers could get really big. The question is when does that happen and how much credit do you give them now.

Write to Andrew Bary at andrew.bary@barrons.com

Excerpt from:
Synthetic Biology Could Be the Next Big Thing. Here Are 3 Stocks. - Barron's

Professor’s Drive to Help the Community Gets Underway for 13th Year | Newsroom – UC Merced University News

Merced is a community with a lot of poverty, made worse with the Great Recession in 2009 and the COVID-19 pandemic. To help people in need, Professor Patti LiWang has been leading a diaper and toilet paper drive for the past 12 years.

When we moved here, the recession hit. It was hard for us, a two-income family, so I understood it must be much harder for one- and low-income families, she said. Then I read an interview with a social worker who said she had seen people re-using diapers and taking napkins from fast-food restaurants for toilet paper. I thought we had to do something.

She arranged to put a donation box in the Science and Engineering 1 Building, where her department, Molecular and Cell Biology, is housed and told everyone she knew about the drive. People began donating, sometimes boxes of diapers, sometimes money. Over the years, a few others put donation boxes in their buildings and helped gather more goods.

LiWang takes the donations to the Merced County Food Bank, which distributes them either directly or through many local food pantries.

Last year, during the pandemic lockdown, LiWang took more monetary donations and gathered some boxes of diapers and packages of toilet paper from peoples front porches and doorsteps contact-free and managed to donate more than 6,000 diapers.

We need all size diapers, all size packages, she said. I usually buy the Target brand because the name-brands are more expensive, but we accept any kind.

The drive has begun for this year. Theres a donation box in S&E1 near the vending machines and one at the Downtown Campus Center near the Public Relations Department on the first floor.

If you would like to host a box in your building and can serve as the point person to let LiWang know when donations are ready for pickup, or if you would like to donate money (cash or checks), email LiWang. She also has a Venmo account, @Patricia-LiWang, to accept donations.

Continued here:
Professor's Drive to Help the Community Gets Underway for 13th Year | Newsroom - UC Merced University News

Unlocking the role of biological clock molecules in cancer cells – Research Matters

An artistic representation of the L-I-C network in cancer cells depicted in the Indian art form, Yakshagana and Somana Kunitha style (Credit Kirti Lathoria)

Our body functions tune to the circadian rhythm the 24- hour day-night cycle. A biological clock comprising special cell components and genes keep track of time and operate synchronously in a complex molecular mechanism. The timekeeping molecules control several crucial physiological processes like metabolism, cell division and proliferation, immune response, and gene expression (decoding genetic information to produce proteins) to maintain the delicate balance of the rhythm. However, science has shown that when the circadian rhythm is severely hampered, some cells break away from the clock control and turn cancerous.

Existing literature shows that cancer cells have an erratic circadian rhythm and abnormal metabolism. Besides, they sustain the onslaught of cytokines from the immune system. However, how exactly these processes promote cancer cell growth has remained elusive.

A team of researchers from the National Brain Research Centre, Manesar, has decoded the interplay between cancer cell metabolism, pro-inflammatory cytokines (inflammation-causing immune molecules), and the biological clock molecules. Their study shows that the cancer cells chemically rewire the production of an inflammation-inducing mediatorIL-1 and lactate - a by-product of cancer cell metabolism. Furthermore, these two components chemically manipulate the clock machinery to trigger further production of lactate and IL-1. Thus the three components work in tandem to promote a vicious loop of tumour growth. The team has published their results in the journal Molecular and Cellular Biology.

The results of this research will provide a framework for cancer chronotherapy a novel treatment method by which anticancer drugs are administered at optimal timings to enhance their chemotherapeutic potential.

The team conducted laboratory experiments on cultured brain cancer cells by employing several molecular testing methods to observe the function of the cell processes.

Cancer cells hoodwink the circadian checkpoints and alter their metabolism to feed the rapidly growing cells. The common feature of cancer cell metabolic reprogramming is glucose addiction a heightened glucose uptake as compared to a normal cell, says Dr Ellora Sen, Principal Investigator of the study. Unlike healthy cells, cancer cells metabolise glucose even in the presence of oxygen. This aerobic glycolysis produces large amounts of lactate, resulting in a highly acidic environment around the tumour a hallmark feature of cancer. Also, the high acidic environment triggers some genes which help tumour growth.

When there is a disease or injury, the immune system dispatches pro-inflammatory cytokines to induce a mild inflammation at the injury site. The inflammation destroys the diseased cells and facilitates healing. IL-1 is once such cytokine released in response to cancerous growths. Our findings indicate that high lactate levels trigger expression of IL-1, says Dr Sen.

The rapidly multiplying cancer cells activate the immune system to send a surge of IL-1 cytokines. In our earlier study, we found that the cancer cells use IL-1 to enhance the expression of another protein called Hexokinase (HK2), which increases the glucose uptake, adds Pruthvi Gowda, first author of the study. With HK2 promoting glucose intake, the cancer cells get more fuel to multiply.

The team then found that high lactate and IL-1 also increased two crucial circadian molecules, Clock and Bmal1. Bmal1 regulates cell division and is bound to the Clock molecule in what is chemically called a transcriptional dimer. In healthy cells, Clock and Bmal1 work in a complementary manner to control cell growth. However, the researchers noticed that both lactate and IL-1 chemically modify Bmal1 to increase the Clock -Bmal1 binding stability.

Further molecular experiments revealed that Clock/Bmal1 activated a Lactate producing enzyme called LDH-A and IL-1, suggesting the presence of a feed-forward network, says Dr Sen. The researchers thus posit that the three components work in a mutually supportive loop that facilitates the rapid growth of the tumour cells.

To establish their results, the team knocked down Clock-Bmal1 molecules in cancer cells. They noticed that downregulating the clock proteins resulted in lower lactate and IL-1 levels. The team further correlated their results for stomach and cervical cancer cell lines and conducted computer simulations on clinical samples data. They observed that patients who had lower Clock, Bmal1, LDHA and IL-1 levels in their samples survived longer.

The team now looks forward to developing a mathematical model for Lactate- IL-1- Clock (LIC) feed-forward regulatory structure in collaboration with IIT Mumbai. When fitted to the patient molecular profile of LIC components, the model could provide valuable inputs for cancer chronotherapy.

This article has been run past the researchers, whose work is covered, to ensure accuracy.

Read the original:
Unlocking the role of biological clock molecules in cancer cells - Research Matters

Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise for B-cell…

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

SAN DIEGO, July 16, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that management will host a virtual event to highlight interim Phase 1 clinical data from its FT596 and FT516 programs for the treatment of relapsed / refractory B-cell lymphomas on August 19, 2021 at 4:30 p.m. ET.

The live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the Company's website at http://www.fatetherapeutics.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event.

About Fate Therapeutics iPSC Product PlatformThe Companys proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Companys first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment. As a result, the Companys platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Fate Therapeutics iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications.

About FT516FT516 is an investigational, universal, off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line engineered to express a novel high-affinity 158V, non-cleavable CD16 (hnCD16) Fc receptor, which has been modified to prevent its down-regulation and to enhance its binding to tumor-targeting antibodies. CD16 mediates antibody-dependent cellular cytotoxicity (ADCC), a potent anti-tumor mechanism by which NK cells recognize, bind and kill antibody-coated cancer cells. ADCC is dependent on NK cells maintaining stable and effective expression of CD16, which has been shown to undergo considerable down-regulation in cancer patients. In addition, CD16 occurs in two variants, 158V or 158F, that elicit high or low binding affinity, respectively, to the Fc domain of IgG1 antibodies. Numerous clinical studies with FDA-approved tumor-targeting antibodies, including rituximab, trastuzumab and cetuximab, have demonstrated that patients homozygous for the 158V variant, which is present in only about 15% of patients, have improved clinical outcomes. FT516 is being investigated in a multi-dose Phase 1 clinical trial as a monotherapy for the treatment of acute myeloid leukemia and in combination with CD20-targeted monoclonal antibodies for the treatment of advanced B-cell lymphoma (NCT04023071). Additionally, FT516 is being investigated in a multi-dose Phase 1 clinical trial in combination with avelumab for the treatment of advanced solid tumor resistant to anti-PDL1 checkpoint inhibitor therapy (NCT04551885).

About FT596FT596 is an investigational, universal, off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with three anti-tumor functional modalities: a proprietary chimeric antigen receptor (CAR) optimized for NK cell biology that targets B-cell antigen CD19; a novel high-affinity 158V, non-cleavable CD16 (hnCD16) Fc receptor, which has been modified to prevent its down-regulation and to enhance its binding to tumor-targeting antibodies; and an IL-15 receptor fusion (IL-15RF) that augments NK cell activity. In preclinical studies of FT596, the Company has demonstrated that dual activation of the CAR19 and hnCD16 targeting receptors enhances cytotoxic activity, indicating that multi-antigen engagement may elicit a deeper and more durable response. Additionally, in a humanized mouse model of lymphoma, FT596 in combination with the anti-CD20 monoclonal antibody rituximab showed enhanced killing of tumor cells in vivo as compared to rituximab alone. FT596 is being investigated in a multi-center Phase 1 clinical trial for the treatment of relapsed / refractory B-cell lymphoma as a monotherapy and in combination with rituximab, and for the treatment of relapsed / refractory chronic lymphocytic leukemia (CLL) as a monotherapy and in combination with obinutuzumab (NCT04245722).

About Fate Therapeutics, Inc.Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Companys immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit http://www.fatetherapeutics.com.

Contact:Christina TartagliaStern Investor Relations, Inc.212.362.1200christina@sternir.com

Go here to read the rest:
Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise for B-cell...

Bioengineering discovery paves way for improved production of bio-based goods using Bakers yeast – Newswise

Newswise Scientists have uncovered a way to control many genes in engineered yeast cells, opening the door to more efficient and sustainable production of bio-based products.

The study, published in Nucleic Acids Research by researchers from DSMs Rosalind Franklin Biotechnology Center in Delft, the Netherlands, and the University of Bristol, has shown how to unlock CRISPRs potential for regulating many genes simultaneously.

Bakers yeast, or Saccharomyces cerevisiae to give it its full name, is considered as a workhorse for biotechnology. Not only has it been used for producing bread and beer for thousands of years, but today it can also be engineered to produce an array of other useful compounds that form the basis of pharmaceuticals, fuels, and food additives. However, achieving optimal production of these products is difficult, requiring the complex biochemical networks inside the cell to be rewired and extended through the introduction of new enzymes and the tuning of gene expression levels.

Klaudia Ciurkot, first author of the study and an EU-funded industrial PhD student based at DSM stated: To overcome the challenges of optimising S. cerevisiae cells for bio-production, we explored the use of a less widely employed CRISPR technology based on the Cas12a protein. Unlike the Cas9 protein that is more commonly used, Cas12a can be rapidly programmed to interact with sequences that are responsible for controlling gene expression and easily targeted to many different sequences at the same time. This made it an ideal platform for carrying out the complex gene regulation often required for producing industrially relevant compounds.

She went on to add: What was particularly exciting for me was that this study is the first to demonstrate Cas12as ability to control gene expression in S. cerevisiae and through joint research across DSM and the University of Bristol, we were able to figure out the rules for how this system is best designed and used.

Thomas Gorochowski, a co-author on the work and Royal Society University Research Fellow based in the School of Biological Sciences at the University of Bristol further stated: It is hugely exciting that Cas12a has been shown to work so well for gene regulation in the yeast S. cerevisiae, an organism that has huge industrial importance. In addition, the systematic approach we have taken to pull apart and analyse the many difficult aspects of the system, act as a firm foundation for future optimisation.

In addition to analysing how the Cas12a-based system is best engineered, the scientists went on to show its use in robustly controlling the production of -carotene an industrially important compound used in production of food additives and nutraceuticals.

Ren Verwaal, senior author and Senior Scientist at DSM ended by stating: By demonstrating the capabilities of this system to control the biosynthesis of -carotene, we have opened the gates to its broader application for other key bio-based products. I cannot wait to see how our system is used to develop more sustainable production platforms for everyday products we all rely on.

The study was funded by the European Unions Horizon 2020 Research and Innovation Programme (ITN SynCrop) under the Marie Skodowska-Curie grant agreement No 764591, BrisSynBio, a BBSRC/EPSRC Synthetic Biology Research Centre, the Royal Society, and supported by the Bristol BioDesign Institute (BBI).

Paper

Efficient multiplexed gene regulation inSaccharomyces cerevisiaeusing dCas12a inNucleic Acids Research by Klaudia Ciurkot, Thomas E. Gorochowski, Johannes A. Roubos and Ren Verwaal.

View post:
Bioengineering discovery paves way for improved production of bio-based goods using Bakers yeast - Newswise